Pisgah Labs Wants to Bulk Up on Controlled Drugs – Comments Welcome!
Published Date: 3/13/2026
Notice
Summary
Pisgah Laboratories Inc wants to become a big-time maker of certain controlled drugs, including some strong medicines and research chemicals. People and companies affected can share their thoughts or ask for a hearing by May 12, 2026. This move could impact drug supply and regulation, but no costs or deadlines beyond the comment period are set yet.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 0 costs, 2 mixed.
Comment Deadline for Manufacturers
If you are a registered bulk manufacturer of controlled substances or an applicant, you may submit electronic comments or objections, or file a written request for a hearing, on Pisgah Laboratories Inc's application on or before May 12, 2026.
Application to Bulk-Produce Specific Drugs
On February 9, 2026 Pisgah Laboratories Inc applied to be registered to bulk manufacture the listed controlled substances (including 4-Bromo-2,5-dimethoxy-phenethylamine (code 7392, Schedule I), Psilocybin (7437, Schedule I), Methylone (7540, Schedule I), and Schedule II drugs such as Amphetamine (1100), Lisdexamfetamine (1205), Methylphenidate (1724), Cocaine (9041), Methadone (9250), and others). The company states it plans bulk manufacture for internal research purposes and distribution to its customers if registered.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in